OncoMatch/Clinical Trials/NCT06781567
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Is NCT06781567 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HG146 for adenoid cystic carcinoma.
Treatment: HG146 — This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HDAC inhibitor
Received prior therapies targeting HDAC.
Cannot have received: chemotherapy
Exception: chemotherapy within 21 days before first administration of study treatment
Chemotherapy was received within 21 days before the first administration of the study treatment
Cannot have received: radiotherapy
Exception: anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy within 28 days before first administration of study treatment
anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days before the first administration of the study treatment
Cannot have received: small molecule targeted drug
Exception: small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy within 14 days before first administration of study drug
small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy were 14 times before the first administration of the study drug
Cannot have received: allogeneic bone marrow transplantation
Prior allogeneic bone marrow transplantation or other solid organ transplantation
Lab requirements
Blood counts
Has adequate organ function.
Kidney function
Has adequate organ function.
Liver function
Has adequate organ function.
Has adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify